Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RT023 in Patients With Advanced Solid Tumors

NCT07797426 is registered in ClinicalTrials.gov with Shanghai Ruotuo Biosciences Co., Ltd. as lead sponsor.

NCT NCT07797426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07797426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RT023 in Patients With Advanced Solid Tumors
Lead sponsor
Shanghai Ruotuo Biosciences Co., Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 12, 2026
Completion date
June 30, 2029
Enrollment
318 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid tumours